LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

29.73 1.33

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

29.04

Максимум

30.1

Ключови измерители
By Trading Economics
Приходи	-339M -94M
Продажби	-82M 32M
EPS	-0.91
Марж на печалбата	-297.177
Служители	522
EBITDA	-362M -102M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+75.44% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-101M 3B
Предишно отваряне	28.4
Предишно затваряне	29.73

Настроения в новините

By Acuity

68%

32%

298 / 344 Класиране в Healthcare

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.06.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8.06.2026 г., 15:41 ч. UTC

Значими двигатели на пазара

American Battery Shares Jump on Energy Department Victory

8.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rebound After Monday's Selloff -- Market Talk

8.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8.06.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Agrees to Buy m3ter

8.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.06.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8.06.2026 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8.06.2026 г., 18:17 ч. UTC

Пазарно говорене

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8.06.2026 г., 17:32 ч. UTC

Пазарно говорене

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.06.2026 г., 16:55 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8.06.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8.06.2026 г., 16:40 ч. UTC

Пазарно говорене

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 16:31 ч. UTC

Пазарно говорене

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8.06.2026 г., 16:27 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in May -- Market Talk

8.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.06.2026 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Orange Bought Stake From Lorca

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Acquires 100% Ownership of MasOrange

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 15:55 ч. UTC

Пазарно говорене

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8.06.2026 г., 15:41 ч. UTC

Пазарно говорене

Gold Falls Below 200-Day Moving Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

75.44% нагоре

12-месечна прогноза

Среден 51.58 USD 75.44%

Висок 80 USD

Нисък 26 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

298 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.